RXST Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.22%, SMA50 19.07%, SMA200 -3.38%). The stock’s 14-day RSI is 56.88 (neutral), while the ATR of 0.68 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.87% below its high and over 90.35% above its low. Average 10-day trading volume of 718.85 thousand shares is in line with the 3-month average of 775.18 thousand, indicating normal recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

RxSight, Inc. has 40.92 million shares outstanding. The public float is 32.44 million shares, elevated short interest at 14.81% of float. This equals 5.77 million shares. The short ratio is 4.86 days. Institutional investors hold 102.64% of the float. Insiders own 5.56%. Kurtz Ronald M MD holds 764.61 thousand shares, Weinberg Eric has 299.98 thousand shares and Goldshleger Ilya has 42.25 thousand shares.

Wall Street analysts project EPS growth of -13.35% annually over the next five years. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.34. Next year's EPS is expected at $18.19. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 7 Buy ratings, 17 Hold ratings, 0 Sell rating and 3 Strong Sell ratings. Price targets range from $66.00 to $8.00. The high target offers 448.63% upside. The low target suggests -33.5% downside. The mean target is $22.00. This offers 82.88% upside. RxSight, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 05, 2025, missed forecasts by -78.95%. The prior quarter beat by -20.0%. Over the last six quarters, Apple has recorded several small beats. These include 125.83% in August 05, 2024.

Our AI price prediction model suggests that RxSight, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.39%, with price expected at $13.52 by January 02, 2026, within a range of $12.93 to $14.09 3-Month Outlook: Projected rise of 30.34%, reaching $15.68 by March 19, 2026, with a range of $14.93 to $16.46. 1-Year Outlook: Projected loss of -26.6%, with price at $8.83 by December 18, 2026, within a range of $0.00 to $0.51.

RxSight, Inc. (NASDAQ:RXST) shares are down -65.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows RxSight, Inc. trading at a premium to the broader market with a P/E of -15.2. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $32.90, suggesting 173.48% upside. Our AI forecast model points to short-term strength (12.39% over two weeks), a medium-term rise (30.34% over three months), and a longer-term loss (-26.6% over one year), with expected trading ranges indicating moderate volatility.

RxSight, Inc. trades at a P/E ratio of -15.2, slightly below the S&P 500 average, with a price-to-sales ratio of 3.15 and a price-to-book ratio of 1.76 suggesting the stock is closer to book value. The P/FCF stands at -23.69, also below market averages.

RxSight, Inc. (NASDAQ:RXST) closed at $12.31 USD, gaining $0.29 (2.37%) from the previous close of $12.03. The stock is currently mid-range between its 52-week high and low $6.32 and $37.13. With a market capitalization of about $506.35 million, RxSight, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.13). Key stats such as the average daily volume over the past year has been around 782.76 thousand shares, volume is running light vs its 52-week average. Headquartered in Aliso Viejo, CA, RxSight, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Ronald Kurtz, the company employs approximately 498 people and listed since July 30, 2021. RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally.